Oxford BioDynamics (LON:OBD) Sets New 52-Week Low – Time to Sell?

Oxford BioDynamics Plc (LON:OBD) hit a new 52-week low on Monday . The stock traded as low as GBX 0.08 and last traded at GBX 0.11, with a volume of 19840916 shares changing hands. The stock had previously closed at GBX 0.11.

Oxford BioDynamics Trading Up 6.7%

The company has a debt-to-equity ratio of 131.61, a quick ratio of 2.80 and a current ratio of 2.01. The company has a market capitalization of £4.81 million, a price-to-earnings ratio of -0.56 and a beta of 0.42. The firm has a fifty day moving average price of GBX 0.17 and a 200-day moving average price of GBX 0.22.

Oxford BioDynamics (LON:OBD) last posted its quarterly earnings data on Tuesday, June 30th. The biotechnology company reported GBX (0.10) earnings per share for the quarter. Oxford BioDynamics had a negative return on equity of 451.74% and a negative net margin of 825.61%.

About Oxford BioDynamics

Oxford BioDynamics Plc is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.

Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.

In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit.